Insmed CMO out the door, headed for 'West Coast'

exitsign
As Paul Streck takes to the exit, Insmed is looking for a new chief medical officer. (Pixabay)

The New Year wanderlust continues as Paul Streck, M.D., will this week exit his role as chief medical officer of Insmed to "pursue an employment opportunity on the West Coast."

That’s all she wrote in terms of details, but the SEC filing says: "Dr. Streck has advised the Company that he intends to work with the Company in an advisory capacity subsequent to his departure to assist in the transition of his responsibilities.

"The Company has commenced a search for Dr. Streck’s successor. Dr. Streck’s resignation does not reflect any disagreement with the Company."

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Bridgewater, New Jersey-based Insmed is working on treatments for lung disease and rare disorders, and in the fall gained a speedy OK from the FDA for Arikayce (amikacin liposome inhalation suspension), approved for patient with mycobacterium avium complex lung disease and as part of a combo antibacterial drug therapy.

In October 2016, Insmed struck a deal with AstraZeneca, which saw the New Jersey biotech gain the rights to its respiratory candidate AZD7986, worth $30 million upfront and $120 million in biobucks. The drug, now known as INS1007, is in phase 2 development.

The company, with a market cap of $1.7 billion, was down 2.7% last night.

This comes amid a mini-exodus across biopharma over the past few weeks, with several big R&D moves out of AstraZeneca/Medimmune, as well as for Novartis and Roche.

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.